Table 2.

Potential strategies toward improved early diagnosis, staging, and response to therapy of canine glaucoma

Detailed clinical and genetic definition of breed‐specific forms of primary glaucoma with similarities and differences with human forms of glaucoma.

Development of more accurate classification of canine glaucoma.

Standardization and development of grading scheme for ultrasound biomicroscopy measurements and ciliary cleft width.

Facilitation of routine direct and indirect measurement of aqueous humor dynamics, such as episcleral venous pressure, tonography, and fluorophotometry, allowing estimation of conventional and unconventional outflow.

Development of continuous tonometry and determination of its value for early diagnosis.*

Definition of safe, healthy target IOP, and its potential individual variability.

Routine assessment of iridocorneal angle morphology and regional variability, including pectinate ligament dysplasia and width of ciliary cleft.

Review and revision of relevant and definable iridocorneal angle classification, including the effect of age and disease.

Validation and comparison of high‐resolution imaging technologies, for both anterior and posterior segment.*

Development of functional techniques, such as electroretinography and pupillometry, for early detection of retinal and optic nerve damage.*

Development of molecular and genetic glaucoma markers for clinical application.

Determination of inter‐individual differences in responsiveness to glaucoma drugs and nonresponder rates.

^*Many of these technologies already exist but need to be validated for canine glaucoma.